Gender affirming hormone therapy dosing behaviors among transgender and nonbinary adults

Arjee Restar (), E. J. Dusic, Henri Garrison-Desany, Elle Lett, Avery Everhart, Kellan E. Baker, Ayden I. Scheim, S. Wilson Beckham, Sari Reisner, Adam J. Rose, Matthew J. Mimiaga, Asa Radix, Don Operario and Jaclyn M. W. Hughto
Additional contact information
Arjee Restar: University of Washington
E. J. Dusic: University of Washington
Henri Garrison-Desany: Johns Hopkins Bloomberg School of Public Health
Elle Lett: Center for Applied Transgender Studies
Avery Everhart: Center for Applied Transgender Studies
Kellan E. Baker: Johns Hopkins Bloomberg School of Public Health
Ayden I. Scheim: Drexel University
S. Wilson Beckham: Johns Hopkins Bloomberg School of Public Health
Sari Reisner: Harvard University
Adam J. Rose: Hebrew University School of Public Health
Matthew J. Mimiaga: UCLA Center for LGBTQ+ Advocacy, Research & Health
Asa Radix: Yale University School of Public Health
Don Operario: Brown University School of Public Health
Jaclyn M. W. Hughto: Brown University School of Public Health

Palgrave Communications, 2022, vol. 9, issue 1, 1-11

Abstract: Abstract Gender-affirming hormones have been shown to improve psychological functioning and quality of life among transgender and nonbinary (trans) people, yet, scant research exists regarding whether and why individuals take more or less hormones than prescribed. Drawing on survey data from 379 trans people who were prescribed hormones, we utilized multivariable logistic regression models to identify factors associated with hormone-dosing behaviors and content analysis to examine the reasons for dose modifications. Overall, 24% of trans individuals took more hormones than prescribed and 57% took less. Taking more hormones than prescribed was significantly associated with having the same provider for primary and gender-affirming care and gender-based discrimination. Income and insurance coverage barriers were significantly associated with taking less hormones than prescribed. Differences by gender identity were also observed. Addressing barriers to hormone access and cost could help to ensure safe hormone-dosing behaviors and the achievement trans people’s gender-affirmation goals.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1057/s41599-022-01291-5 Abstract (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:pal:palcom:v:9:y:2022:i:1:d:10.1057_s41599-022-01291-5

Ordering information: This journal article can be ordered from
https://www.nature.com/palcomms/about

DOI: 10.1057/s41599-022-01291-5

Access Statistics for this article

More articles in Palgrave Communications from Palgrave Macmillan
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().